| Bioactivity | SKI-II is an oral active and synthetic inhibitor of sphingosine kinase (SK) activity, with IC50 values of 78 μM and 45 μM for SK1 and for SK2, respectively. SKI II causes an irreversible inhibition of SK1 by inducing its lysosomal and/or proteasomal degradation[1][2]. | ||||||||||||
| Invitro | SKI II inhibits cell proliferation by suppressing the Wnt/β-catenin signaling pathway. SKI II promotes the degradation of β-catenin by enhancing Wnt5A[1].SKI II (1.25 μM, 48 h) in combination with DDP has a clear synergistic effect in human gastric carcinoma SGC7901/DDP cell line[2]. Cell Cytotoxicity Assay[1] Cell Line: | ||||||||||||
| Name | SKI II | ||||||||||||
| CAS | 312636-16-1 | ||||||||||||
| Formula | C15H11ClN2OS | ||||||||||||
| Molar Mass | 302.78 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|